Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2001-09-12
2004-06-22
Souaya, Jehanne (Department: 1634)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023700, C536S024300
Reexamination Certificate
active
06753417
ABSTRACT:
BACKGROUND OF THE INVENTION
I. Field of the Invention
The present invention relates generally to the fields of microbiology, and clinical bacteriology. More particularly, it concerns sequences of the uspA1 and uspA2 genes which encode the proteins UspA1 and UspA2, respectively, both of which encode an epitope reactive with monoclonal antibody (MAb) 17C7 and provide useful epitopes for immunodiagnosis and immunoprophylaxis.
II. Description of Related Art
It was previously thought that
Moraxella catarrhalis
, previously known as
Branhamella catarrhalis
or
Neisseria catarrhalis
, was a harmless saprophyte of the upper respiratory tract (Catlin, 1990; Berk, 1990). However, during the previous decade, it has been determined that this organism is an important human pathogen. Indeed, it has been established that this Gram-negative diplococcus is the cause of a number of human infections (Murphy, 1989).
M. catarrhalis
is now known to be the third most common cause of both acute and chronic otitis media (Catlin, 1990; Faden et al., 1990; 1991; Marchant, 1990), the most common disease for which infants and children receive health care according to the 1989 Consensus Report. This organism also causes acute maxillary sinusitis, generalized infections of the lower respiratory tract (Murphy and Loeb, 1989) and is an important cause of bronchopulmonary infections in patients with underlying chronic lung disease and, less frequently, of systemic infections in immunocompromised patients (Melendez and Johnson, 1990; Sarubbi et al., 1990; Schonheyder and Ejlertsen, 1989; Wright and Wallace, 1989).
The 1989 Consensus Report further concluded that prevention of otitis media is an important health care goal due to both its occurrence in infants and children, as well as certain populations of all age groups. In fact, the total financial burden of otitis media has been estimated to be at least $2.5 billion annually. Vaccines were identified as the most desired approach to prevent this disease for a number of reasons. For example, it was estimated that if vaccines could reduce the incidence of otitis media by 30%, then the annual health care savings would be at least $400 million. However, while some progress has been made in the development of vaccines for 2 of the 3 common otitis media pathogens,
Streptococcus pneumoniae
and
Haemophilus influenzae
, there is no indication that similar progress has been made with respect to
M. catarrhalis
. This is particularly troublesome in that
M. catarrhalis
now accounts for approximately 17-20% of all otitis media infection (Murphy, 1989). In addition,
M. catarrhalis
is also a significant cause of sinusitis (van Cauwenberge et al., 1993) and persistent cough (Gottfarb and Brauner, 1994) in children. In the elderly, it infects patients with predisposing conditions such as chronic obstructive pulmonary disease (COPD) and other chronic cardiopulmonary conditions (Boyle et al., 1991; Davies and Maesen, 1988; Hager et al., 1987).
Despite its recognized virulence potential, little is known about the mechanisms employed by
M. catarrhalis
in the production of disease or about host factors governing immunity to this pathogen. An antibody response to
M. catarrhalis
otitis media has been documented by means of an ELISA system using whole
M. catarrhalis
cells as antigen and acute and convalescent sera or middle ear fluid as the source of antibody (Leinonen et al., 1981). The development of serum bactericidal antibody during
M. catarrhalis
infection in adults was shown to be dependent on the classical complement pathway (Chapman et al., 1985). And more recently, it was reported that young children with
M. catarrhalis
otitis media develop an antibody response in the middle ear but fail to develop a systemic antibody response in a uniform manner (Faden et al., 1992).
Previous attempts have been made to identify and characterize
M. catarrhalis
antigens that would serve as potentially important targets of the human immune response to infection (Murphy, 1989; Goldblatt et al., 1990; Murphy et al, 1990). Generally speaking, the surface of
M. catarrhalis
is composed of outer membrane proteins (OMPs), lipooligosaccharide (LOS) and fimbriae.
M. catarrhalis
appears to be somewhat distinct from other Gram-negative bacteria in that attempts to isolate the outer membrane of this organism using detergent fractionation of cell envelopes has generally proven to be unsuccessful in that the procedures did not yield consistent results (Murphy, 1989; Murphy and Loeb, 1989). Moreover, preparations were found to be contaminated with cytoplasmic membranes, suggesting an unusual characteristic of the
M. catarrhalis
cell envelope.
Passive immunization with polyclonal antisera raised against outer membrane vesicles of the
M. catarrhalis
strain O35E was also found to protect against pulmonary challenge by the heterologous
M. catarrhalis
strain TTA24. In addition, active immunization with
M. catarrhalis
outer membrane vesicles resulted in enhanced clearance of this organism from the lungs after challenge. The positive effect of immunization in pulmonary clearance indicates that antibodies play a major role in immunoprotection from this pathogen. In addition, the protection observed against pulmonary challenge with a heterologous
M. catarrhalis
strain demonstrates that one or more conserved surface antigens are targets for antibodies which function to enhance clearance of
M. catarrhalis
from the lungs.
Outer membrane proteins (OMPs) constitute major antigenic determinants of this unencapsulated organism (Bartos and Murphy, 1988) and different strains share remarkably similar OMP profiles (Bartos and Murphy, 1988; Murphy and Bartos, 1989). At least thee different surface-exposed outer membrane antigens have been shown to be well-conserved among
M. catarrhalis
strains; these include the 81 kDa CopB OMP (Helminen et al., 1993b), the heat-modifiable CD OMP (Murphy et al., 1993) and the high-molecular weight UspA antigen (Helminen et al., 1994). Of these three antigens, both the CopB protein and UspA antigen have been shown to bind antibodies which exert biological activity against
M. catarrhalis
in an animal model (Helminen al., 1994; Murphy et al., 1993).
The MAb, designated 17C7, was described as binding to UspA, a very high molecular weight protein that migrated with an apparent molecular weight (in SDS-PAGE) of at least 250 kDa (Helminen et al., 1994; Klingman and Murphy, 1994). MAb 17C7 enhanced pulmonary clearance of
M. catarrhalis
from the lungs of mice when used in passive immunization studies and, in colony blot radioimmunoassay analysis, bound to every isolate of
M. catarrhalis
examined. This same MAb also reacted, although less intensely, with another antigen band of approximately 100 kDa, as described in U.S. Pat. No. 5,552,146 (incorporated herein by reference). A recombinant bacteriophage that contained a fragment of
M. catarrhalis
chromosomal DNA that expressed a protein product that bound MAb 17C7 was also identified and migrated at a rate similar or indistinguishable from that of the native UspA antigen from
M. catarrhalis
(Helminen et al., 1994).
With the rising importance of this pathogen in respiratory tract infections, identification of the surface components of this bacterium involved in virulence expression and immunity is becoming more important. To date, there are no vaccines available, against any other OMP, LOS or fimbriae, that induce protective antibodies against
M. catarrhalis
. Thus, it is clear that there remains a need to identify and characterize useful antigens and which can be employed in the preparation of immunoprophylactic reagents. Additionally, once such an antigen or antigens is identified, there is a need for providing methods and compositions which will allow the preparation of vaccines and in quantities that will allow their use on a wide scale basis in prophylactic protocols.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide new UspA1 and UspA2 proteins and genes codin
Aebi Christoph
Cope Leslie D.
Fiske Michael J.
Fredenburg Ross A.
Hansen Eric J.
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Souaya Jehanne
LandOfFree
UspA1 and UspA2 antigens of Moraxella catarrhalis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with UspA1 and UspA2 antigens of Moraxella catarrhalis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and UspA1 and UspA2 antigens of Moraxella catarrhalis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3339133